News|Articles|November 17, 2026

5 FDA Approvals From This Fall That People With Cancer Should Know

Fact checked by: CURE staff
Listen
0:00 / 0:00

From colon and rectal cancer to bladder and head and neck cancers, here are five FDA approvals from fall 2026 and what they mean for patients.

Fall has been a busy season for cancer treatment. Between mid-September and mid-November, the Food and Drug Administration (FDA) announced more than a dozen cancer approvals, ranging from new pills to new uses for immunotherapies already on the market.

Here are five that change options for common cancers, listed in the order they were approved, along with what each means for patients. Each one links to CURE's full coverage.

A Few Terms That Will Help

Several of these approvals depend on what's inside the tumor. Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) tumors have trouble fixing errors in their DNA, which makes them more visible to the immune system. An accelerated approval lets the FDA approve a treatment based on early signs of benefit, such as tumor shrinkage, while further studies confirm it. When a trial says a treatment "lowered the risk" of the cancer growing, returning or causing death by a certain percentage, it is comparing the new treatment with the standard approach.

1. Tecentriq Plus Chemotherapy After Surgery for Stage 3 dMMR Colon Cancer

Approved: Oct. 8

The FDA approved Tecentriq (atezolizumab) with a fluoropyrimidine and oxaliplatin, two types of chemotherapy, as an after-surgery treatment for adults and children 2 years and older with stage 3 dMMR colon cancer. A version given as an injection under the skin, Tecentriq Hybreza, was approved for patients 12 and older who weigh at least 40 kilograms.

In the ATOMIC trial of 711 adults and one child, people who received Tecentriq plus chemotherapy had a 50% lower risk of their cancer returning or death than those who received chemotherapy alone. The prescribing information warns of immune-related side effects, in which the immune system can affect healthy organs.

What it means: If you have stage 3 colon cancer, ask whether your tumor was tested for mismatch repair status. A dMMR result now opens the door to adding immunotherapy after surgery. Read CURE's coverage of the approval.

2. Jemperli for dMMR or MSI-H Locally Advanced Rectal Cancer

Approved: Oct. 19 (accelerated approval)

Jemperli (dostarlimab) is now approved for adults with stage 2 or 3 locally advanced rectal cancer that is MSI-H or dMMR, confirmed with an FDA-authorized test. Standard treatment for this cancer often combines chemotherapy, radiation and surgery, which can affect bowel, bladder and sexual function and sometimes requires a permanent ostomy.

In the AZUR-1 trial, 154 people received Jemperli by IV every three weeks for nine cycles. Of those, 110 (71%) received Jemperli alone, needed no other treatment and did not see their cancer progress. Among the 116 patients independent reviewers could evaluate, 47% had a clinical complete response, meaning no sign of the tumor on exams and scans, that lasted at least 12 months.

What it means: For people with this type of rectal cancer, immunotherapy alone may make it possible to skip surgery and radiation. Patients whose tumors disappear move into a "watch-and-wait" plan with frequent checkups, so ask your team what that monitoring involves. Read CURE's coverage of the approval.

3. Talzenna Plus Xtandi for Hormone-Sensitive Prostate Cancer With HRR Mutations

Approved: Oct. 26

The FDA approved Talzenna (talazoparib) with Xtandi (enzalutamide) for adults with metastatic prostate cancer that has not yet been treated with, or is still responding to, drugs that block the androgen (male hormone) pathway, and that has mutations in homologous recombination repair (HRR) genes. HRR genes, which include BRCA1 and BRCA2, help cells repair damaged DNA. The combination was already approved for some people whose prostate cancer no longer responds to standard hormone therapy.

In the TALAPRO-3 trial of 599 patients, Talzenna plus Xtandi lowered the risk of the cancer growing or death by 52% compared with placebo plus Xtandi. Talzenna's prescribing information includes warnings for low blood counts and for the blood cancers myelodysplastic syndrome and acute myeloid leukemia, so regular blood tests are needed during treatment.

What it means: Genetic testing of the tumor tissue or blood can now shape treatment early in metastatic prostate cancer. FDA-approved companion tests can identify who may be eligible. Read CURE's coverage of the approval.

4. Rybrevant Faspro for Recurrent or Metastatic Head and Neck Cancer

Approved: Nov. 5 (accelerated approval)

Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), an injection under the skin that targets the EGFR and MET proteins, is now approved for adults with head and neck squamous cell carcinoma that came back or spread after platinum-based chemotherapy and a PD-1 or PD-L1 immunotherapy. It is not approved for HPV-associated cancer of the back of the throat. This is the drug's first approval outside of lung cancer.

In the OrigAMI-4 trial of 102 adults, 42% had their tumors shrink or disappear, and 15% had no remaining signs of cancer on scans. Among those who responded, 56% kept their response for more than six months. Rash was the most common side effect, affecting 79% of patients.

What it means: People whose head and neck cancer has grown after immunotherapy have a new option. Ask about your tumor's HPV status, and plan ahead with your team for skin care and sun protection. Read CURE's coverage of the approval.

5. Imfinzi Plus Padcev Before and After Surgery for Muscle-Invasive Bladder Cancer

Approved: Nov. 13

The FDA approved Imfinzi (durvalumab) with Padcev (enfortumab vedotin-ejfv) for adults with muscle-invasive bladder cancer who can't receive, or choose not to receive, cisplatin-based chemotherapy. Patients receive both drugs before radical cystectomy, a surgery to remove the bladder, and then continue on Imfinzi alone afterward.

In the VOLGA trial of 695 people, those who received Imfinzi and Padcev had a 49% lower risk of their cancer worsening so surgery was no longer possible, returning after surgery or causing death, compared with surgery alone. The combination also lowered the risk of death by 42%.

What it means: People who can't get cisplatin, a common reason for going straight to surgery, now have an approved treatment option around surgery that helped people live longer. Read CURE's coverage of the approval.

Which Other Cancer Treatments Did the FDA Approve This Fall?

Other approvals this fall include Inluriyo plus Verzenio for ESR1-mutated advanced breast cancer (Sept. 18), Lyrfigtu for FGFR2-positive bile duct cancer (Sept. 23), Welireg plus Lenvima for advanced kidney cancer (Sept. 24), Jaypirca as a first treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma (Oct. 2), Tukysa as maintenance treatment for HER2-positive breast cancer (Oct. 7), an expanded use of Anktiva for bladder cancer that no longer responds to BCG (Oct. 14) and Pimjetmi for tenosynovial giant cell tumor (Nov. 10).

What Should Patients Do With This Information?

Three of these five approvals depend on a specific test result, whether that's mismatch repair status, HRR gene mutations or HPV status. If you have one of these cancers, ask your care team which tests your tumor has had, whether any of these treatments could fit your situation and what side effects to watch for.

References

  1. FDA approves atezolizumab in combination with chemotherapy for stage III mismatch repair deficient colon cancer. U.S. Food and Drug Administration. Oct. 8, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer
  2. FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer. U.S. Food and Drug Administration. Oct. 19, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
  3. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations. U.S. Food and Drug Administration. Oct. 26, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
  4. FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma. U.S. Food and Drug Administration. Nov. 5, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and
  5. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. U.S. Food and Drug Administration. Nov. 13, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
  6. Oncology (cancer)/hematologic malignancies approval notifications. U.S. Food and Drug Administration. Accessed Nov. 16, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Related to this article